Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.51 |
| ▸ | MPL | P40238 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 5/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29993395 | 1.00 | ALDH1A1 (0.53) | ALDH1A1KDM4ELIMK1MPLNPC1 | |
| SCHEMBL11953304 | 0.81 | LIMK1 (0.54) | ALDH1A1KDM4ELIMK1NPC1MAPT | |
| SCHEMBL25375220 | 0.79 | LIMK1 (0.56) | ALDH1A1KDM4ELIMK1NPC1MAPT | |
| SCHEMBL30482474 | 0.79 | LIMK1 (0.56) | ALDH1A1KDM4ELIMK1NPC1MAPT | |
| SCHEMBL15641400 | 0.79 | CLK1 (0.43) | ALDH1A1KDM4ELIMK1NPC1MAPT | |
| SCHEMBL19981533 | 0.78 | LIMK1 (0.55) | ALDH1A1KDM4ELIMK1NPC1MAPT | |
| SCHEMBL30513213 | 0.78 | LIMK1 (0.72) | ALDH1A1KDM4ELIMK1NPC1MAPT | |
| SCHEMBL5536337 | 0.78 | CASR (0.42) | ALDH1A1KDM4EMPLNPC1FEN1 | |
| SCHEMBL38544 | 0.78 | LIMK1 (0.72) | ALDH1A1KDM4ELIMK1NPC1MAPT | |
| SCHEMBL5536331 | 0.78 | KDM4E (0.41) | ALDH1A1KDM4EMPLNPC1FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3741757-B1 | DIHYDROINDOLIZINONE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2023-07-26 | — | — | EP | disclosed |
| CN-111630052-B | Dihydroindazinone derivatives | 第一三共株式会社 | 2023-04-18 | — | — | CN | disclosed |
| US-11530211-B2 | Dihydroindolizinone derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-12-20 | — | — | US | disclosed |
| US-20220339260-A1 | METHOD FOR PRODUCING INSULIN-PRODUCING CELL USING DIHYDROINDOLIZINONE DERIVATIVES | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2022-10-27 | — | — | US | disclosed |
| EP-3998107-A1 | METHOD FOR PRODUCING INSULIN-PRODUCING CELL USING DIHYDROINDOLIZINONE DERIVATIVES | Tokyo Institute of Technology (JP) | 2022-05-18 | — | — | EP | disclosed |
| CN-114040966-A | Method for producing insulin-producing cell using dihydroindolizinone derivative | 国立大学法人东京工业大学 | 2022-02-11 | — | — | CN | disclosed |
| US-20210053965-A1 | DIHYDROINDOLIZINONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-02-25 | — | — | US | disclosed |
| EP-3741757-A1 | DIHYDROINDOLIZINONE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2020-11-25 | — | — | EP | disclosed |
| CN-111630052-A | Dihydroindazinone derivatives | 第一三共株式会社 | 2020-09-04 | — | — | CN | disclosed |
| EP-2719696-A1 | NOVEL KINASE INHIBITORS | Asinex Limited (RU) | 2014-04-16 | — | — | EP | disclosed |
| WO-2012169934-A1 | NOVEL KINASE INHIBITORS | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "АСИНЭКС МЕДХИМ" (RU) | 2012-12-13 | — | — | WO | disclosed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530211-B2 | Dihydroindolizinone derivative | INSR, GPR119, IAPP | ALDH1A1 55/4885KDM4E 1470/4885LIMK1 2419/4885 |
| US-20220339260-A1 | METHOD FOR PRODUCING INSULIN-PRODUCING CELL USING DIHYDROINDOLIZINONE DERIVATIVES | IAPP, INSR, GPR119 | ALDH1A1 422/4885KDM4E 1308/4885LIMK1 2390/4885 |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | ALDH1A1 2292/4885KDM4E 452/4885LIMK1 4439/4885 |
| US-20210053965-A1 | DIHYDROINDOLIZINONE DERIVATIVE | INSR, GPR119, IAPP | ALDH1A1 55/4885KDM4E 1470/4885LIMK1 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.